StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

DRREDDY — DR. REDDY S LABORATORIES

Structural concernsWeak profitabilityInstitutions reducing stake

Price History

Data as of 26 Jun 2026· via fincrux

How DRREDDY has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range98% of range

Trading about 17% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹1,157 low₹1,355 high
vs 50-day avg
+4.3%
vs 200-day avg
+6.7%
Beginner mode
Plain English, with everything explained

DRREDDY

NSE

DR. REDDY S LABORATORIES

Healthcare / Pharma

₹1,350.50
0.00%
last close
0%
Quality Score
Several red flagsBig money selling

DR. REDDY S LABORATORIES clears only 1 of 3 checks. The numbers flag real concerns — exactly the kind of thing that gets lost in exciting news or social-media buzz. Tread carefully.

Company size
₹106178.00 Cr
Price tag
33.0×
Money it earns
10.7%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.18goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Divergent

Profits relative to the money invested are on the weaker side over the last few years.

ROE 10.7%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Divergent

Professional investors have been reducing their stake recently.

FII+DII 51.9%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), g…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What DRREDDY owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings2,205517933,4935,737
Equity Capital8383838384
Reserves18,25320,39124,15728,77331,282
Total Assets24,49625,37530,35938,29143,602
Total Liabilities24,49625,37530,35938,29143,602

Borrowings rising

Total borrowings are up about 160% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for DRREDDY — does it earn money consistently?

Consistently profitable

Every one of the last 5 years has been profitable — a sign of durable earnings.

₹1,623 Cr
₹2,613 Cr
₹4,342 Cr
₹5,349 Cr
₹3,220 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹14,405 Crrev ₹16,962 Crrev ₹19,484 Crrev ₹23,115 Crrev ₹20,533 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about DRREDDY — observations, not recommendations.

Strengths

2
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Profitable in every one of the last 5 years.

Risks

3
  • Profit generated from the money invested has been on the weaker side.
  • Large professional investors have been trimming their stake recently.
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
21.1%-4.2 pp
DII· Domestic institutions
30.7%+4.0 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector